Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anti-inflammatory or immunosuppressive Age: Adult |
Dose: Intramuscular – 10-80 mg Frequency: once daily Note: As methyprednisolone Na succinate |
|
Indication: Anti-inflammatory or immunosuppressive Age: Adult |
Dose: Injection – 10-500 mg Frequency: once daily Note: As methylprednisolone Na succinate. Doses less than 250 mg are given by injection over at least 5 minutes while doses greater than 250 mg are given slowly over at least 30 minutes. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anti-inflammatory or immunosuppressive Age: Child |
Dose: Intramuscular – 0.5-1.7 mg/kg or 5-25 mg/m2 Frequency: daily in divided doses every 6-12 hours Note: as methylprednisolone sodium succinate |
|
Indication: Anti-inflammatory or immunosuppressive (Pulse therapy) Age: Child |
Dose: Intramuscular – 15-30 mg/kg/dose Frequency: once daily Duration: for 3 days Note: given over greater than 30 minutes |
Administration
- For IV/IM injection only
- Must be reconstituted before use
Side Effect
- Allergic or hypersensitivity reactions
- anaphylactoid reaction
- anaphylaxis
- angioedema
- Bradycardia
- cardiac arrest
- cardiac arrhythmias
- cardiac enlargement
- circulatory collapse
- congestive heart failure
- fat embolism
- hypertension
- hypertrophic cardiomyopthy in premature infants
- myocardial rupture following recent mycocardial infarction
- pulmonary edema
- syncope
- tachycardia
- thromboembolism
- thrombophlebitis
- vasculitis
- Acne
- allergic dermatitis
- cutaneous and subcutaneous atrophy
- dry scaly skin
- ecchymoses and petechiae
- edema
- erythema
- hyperpigmentation
- hypopigmentation
- impaired wound healing
- increase sweating
- rash
- sterile abscess
- striae
- suppressed reactions to skin tests
- thin fragile skin
- thinning scalp hair
- urticaria
- Decreased carbohydrate and glucose tolerance
- development of cushingoid state
- glycosuria
- hirsutism
- hypertrichosis
- increased requirements for insulin or oral hypoglycemic agents in diabetes
- manifestations of latent diabetes mellitus
- menstrual irregularities
- secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery or illness)
- suppression of growth in pediatric patients
- Congestive heart failure in susceptible patients
- Fluid retention
- hypokalemic alkalosis
- potassium loss
- sodium retention
- Abdominal distention
- bowel/bladder dysfunction (after intrathecal administration)
- elevation in serum liver enzymes levels (usually reversible upon discontinuation)
- hepatomegaly
- increased appetite
- nausea
- pancreatitis
- peptic ulcer with possible subsequent perforation and hemorrhage
- perforation of the small and large intestine (particularly in patients with inflammatory bowel disease)
- ulcerative esophagitis
- Aseptic necrosis of femoral and humeral heads
- calcinosis (following intra-articular or intra-lesional use)
- Charcot-like arthropathy
- loss of muscle mass
- muscle weakness
- osteoporosis
- pathologic fracture of long bones
- postinjection flare (following intra-articular use)
- steroid myopathy
- tendon rupture
- vertebral compression fractures
- Convulsions
- depression
- emotional instability
- euphoria
- headache
- increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment
- insomnia
- mood swings
- neuritis
- neuropathy
- paresthesia
- personality changes
- psychic disorders
- vertigo
- Exophthalmoses
- glaucoma
- increased intraocular pressure
- posterior subcapsular cataracts
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Vaccines (live organism)
|
May increase the risk of vaccinal infection
|
|
Anticholinesterases
|
Decreases effect in myasthenia gravis
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Protect from light. Store at controlled room temperature 20° to 25°C. Use solution within 48 hours after mixing.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.